COMP <GO>
GYRE vs CTMX // EV/EBITDA & P/E VALUATION
Gyre Therapeutics Inc. (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GYRE 7
— CTMX 2
■ METRIC PARITY
LAST: $4.56 (-28.94%) • MKT CAP: $507.9M
valuation
53.3x
LAST: $2.34 (+2.18%) • MKT CAP: $509.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. CTMX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | CTMX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | -20.50% | +45.90 | GYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 53.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | -15.19% | +15.16 | GYRE | /fcf-yield <GO> |
| Operating Margin | 9.90% | -29.30% | +39.20 | GYRE | /operating-margins <GO> |
| Net Profit Margin | 8.50% | -22.80% | +31.30 | GYRE | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | -44.80% | +55.00 | GYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 0.20 | +14.13 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 1/9 | +4.00 | GYRE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.0 | 43.5 | -5.50 | CTMX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.9M | $509.9M | -$2.0M | CTMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | CTMX REV | GYRE GROSS % | CTMX GROSS % | GYRE FCF | CTMX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $76.2M | 95.4% | — | -$180.0K | -$75.8M |
| FY 2024 | $105.8M | $138.1M | 96.3% | — | -$6.0M | -$86.5M |
| FY 2023 | $113.5M | $101.2M | — | — | $25.9M | -$56.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
CTMX // BETA —